Testing a urine test for bladder cancer recurrence
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new urine test (BCDx) to see if it can catch bladder cancer coming back in people with non-muscle invasive bladder cancer (NMIBC) who are already having regular check-ups. You would give a urine sample before your routine cystoscopy, and the results may help doctors monitor your cancer more easily.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with non-muscle invasive bladder cancer (NMIBC) in the last 2 years, and are getting a routine cystoscopy (a camera test to look inside your bladder) to check if the cancer has come back
- You can give a urine sample of at least 30 mL (about 2 tablespoons)
- You are not planning to have your bladder removed (radical cystectomy) or to receive chemotherapy with radiation for bladder cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a urine test that may help find bladder cancer early without needing invasive procedures. It is for people with high-grade or high-risk non-muscle-invasive bladder cancer who are receiving or have received BCG treatment.
This trial tests a new blood test that looks for signs bladder cancer may be coming back in people with a recent history of bladder cancer. It may help by making surveillance easier, but you must still follow a scheduled bladder-check plan.
This trial checks whether a new lab test on urine can help sort out which people with small amounts of blood in the urine (microscopic hematuria) might have bladder cancer. It may help doctors evaluate symptoms more accurately and decide who needs further testing.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This study examines whether a simple blood test can detect cancer DNA (circulating tumor DNA, or ctDNA) in patients with a specific type of bladder cancer. Detecting this DNA in blood may help doctors predict how the cancer will behave and guide future treatment decisions.
This study uses a urine test to detect small amounts of cancer DNA (microscopic residual disease) after treatment, to see if it can catch a recurrence earlier than standard scans or cystoscopy. It includes four groups of people with different types and stages of urothelial cancer (in the kidney, ureter, or bladder) to see how well the test works for each group.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.